«There is strong evidence that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study»: [more]
I was lucky enough to be in the right place at the right time to witness one of the great turning points in our approach to cancer. In March 1973, a medical student at Milan [more]
The best chance of being cured of cancer is through surgery by expert surgeons with a deep knowledge of oncology. Why then are the public, patients and policy makers so focused on drugs, and does [more]
Looking for anticancer activity among off-patent drugs that are already approved to treat other conditions might seem a sensible way to speed up access to affordable new therapy options. Linda Geddes asks how such a [more]
As researchers, regulatory bodies and health systems give patients more of a voice in consultation and decision making, advocacy groups are questioning what it really means to represent the patient view. Simon Crompton reports. Nothing [more]
Based in a large Paris hospital, breast cancer specialist Joseph Gligorov feels privileged to be able to offer his patients a very high standard of care. He talks to Anna Rouillard about his efforts to [more]
A narrow focus on cancer prevention, detection and care can only succeed as part of wider efforts to strengthen public health systems.The cancer community needs to start playing its part in that effort. Health systems [more]
Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo Casali, a leading expert, presents an update of the latest evidence on the best way to [more]
Mortality data show that a precipitous rise in deaths from cutaneous melanoma in countries of northern Europe, Australia and north America, which started in the 1950s, may now be stabilising. Yet a paper published last [more]
The chances of surviving a childhood cancer have changed very little over the past two decades. Sophie Fessl talked to parents, doctors, regulators and researchers about what has to be done to address this disastrous [more]
Starting next year, trial sponsors can negotiate ethical approval in a member state of their choice, and have the same terms applied across all EU countries. Daniela Ovadia looks at the implications of the new regulation [more]
Standards of care are not yet defined for patients with recurrent glioblastoma. In this critical review, Katharina Seystahl and colleagues summarise the available literature for patients with recurrent (progressive) glioblastoma treated with repeat surgery, re-irradiation, [more]
Patients who have run out of options don’t have time to wait for lengthy trials. But they also need treatments that offer proven benefit, and not just hope. Peter McIntyre asks whether we can speed [more]